NCT04026178View on ClinicalTrials.gov

Immunogenicity of Metreleptin in Patients With Generalized Lipodystrophy

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

November 14, 2018

Primary Completion Date

October 31, 2024

Study Completion Date

April 30, 2025

Conditions
Generalized Lipodystrophy
Interventions
DRUG

Metreleptin

Subjects will receive prescribed dosage of metreleptin as indicated in the USPI

Trial Locations (8)

19104

Childrens Hospital of Philadelphia, Philadelphia

35294

Univ. Alabama-Birmingham, Birmingham

43201

Endocrinology Research Associates, Columbus

43203

Ohio State University, Columbus

48109

University of Michigan, Ann Arbor

70121

Ochsner Clinic, New Orleans

75390

University Texas Southwestern INT, Dallas

98105

Seattle Children's Hospital, Seattle

Sponsors
All Listed Sponsors
lead

Aegerion Pharmaceuticals, Inc.

INDUSTRY